Literature DB >> 20457428

Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis.

Chih-Huan Chung1, Chi-Jung Wu, Hsin-Chun Lee, Jing-Jou Yan, Chia-Ming Chang, Nan-Yao Lee, Po-Lin Chen, Ching-Chi Lee, Yuan-Pin Hung, Wen-Chien Ko.   

Abstract

BACKGROUND/
PURPOSE: An increase in incidence of Clostridium difficile infection (CDI) among Western countries has been noted in recent years. Epidemiological data of CDI are scarce in Taiwan. This study is intended to depict the clinical features of CDI at a medical center in Southern Taiwan.
METHODS: From January 1, 2007 to March 31, 2008, hospitalized patients with CDI (defined as the presence of gastrointestinal symptoms and fecal C. difficile toxin) were identified. Their medical records were reviewed for further evaluation.
RESULTS: A total of 86 cases of CDI were identified in the study period. The incidence was 42.6 cases per 100,000 patient-days, or 3.4 cases per 1,000 discharges, and was highest in intensive care units (110.6 cases per 100,000 patient-days). Variable incidence rates were noted in different wards, and prevalence was higher in the infectious ward. Diarrhea, fever, and abdominal distension were common in 82 (95.3%), 47 (54.7%), and 29 (33.7%) patients, respectively. Metronidazole was the initial therapeutic regimen for 83 (96.5%) patients. Prolonged diarrhea was noted in 31 (36.4%) patients, especially in those on hemodialysis therapy. Recurrence was noted in 7 (8.1%) patients. Fecal carriage of vancomycin-resistant Enterococcus colonization was found in three patients after therapy for CDI. All-cause mortality rate of patients with CDI at 30 days was 23.3%.
CONCLUSION: CDI is increasingly being recognized within the medical departments, and should be considered in hospitalized adults with diarrhea, fever, or abdominal distension alone, or in combination. Copyright 2010 Taiwan Society of Microbiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457428     DOI: 10.1016/S1684-1182(10)60019-9

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  15 in total

1.  Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.

Authors:  Chun-Hsing Liao; Wen-Chien Ko; Jang-Jih Lu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

Review 3.  Clostridium difficile Infection.

Authors:  Jae Hyun Shin; Esteban Chaves-Olarte; Cirle A Warren
Journal:  Microbiol Spectr       Date:  2016-06

4.  Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.

Authors:  Harsh Mathur; Paula M O'Connor; Colin Hill; Paul D Cotter; R Paul Ross
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

5.  Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan.

Authors:  Yuan-Pin Hung; Pei-Jane Tsai; Kuei-Hsiang Hung; Hsiu-Chuan Liu; Chih-I Lee; Hsiao-Ju Lin; Yi-Hui Wu; Jiunn-Jong Wu; Wen-Chien Ko
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

6.  Mortality and Clostridium difficile infection: a review.

Authors:  Brett G Mitchell; Anne Gardner
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-30       Impact factor: 4.887

7.  Characteristics of patients with Clostridium difficile infection in Taiwan.

Authors:  Y-C Lin; Y-T Huang; T-F Lee; N-Y Lee; C-H Liao; S-Y Lin; W-C Ko; P-R Hsueh
Journal:  Epidemiol Infect       Date:  2012-12-06       Impact factor: 4.434

8.  Risk factors of fecal toxigenic or non-toxigenic Clostridium difficile colonization: impact of Toll-like receptor polymorphisms and prior antibiotic exposure.

Authors:  Yuan-Pin Hung; Hsiao-Ju Lin; Tai-Chieh Wu; Hsiu-Chuan Liu; Jen-Chieh Lee; Chih-I Lee; Yi-Hui Wu; Lei Wan; Pei-Jane Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

Review 9.  Parameters for the mathematical modelling of Clostridium difficile acquisition and transmission: a systematic review.

Authors:  Eroboghene H Otete; Anand S Ahankari; Helen Jones; Kirsty J Bolton; Caroline W Jordan; Tim C Boswell; Mark H Wilcox; Neil M Ferguson; Charles R Beck; Richard L Puleston
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

Review 10.  Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.

Authors:  Yuan-Pin Hung; Jen-Chieh Lee; Hsiao-Ju Lin; Hsiao-Chieh Liu; Yi-Hui Wu; Pei-Jane Tsai; Wen-Chien Ko
Journal:  Antibiotics (Basel)       Date:  2015-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.